Drugs / RO7496353
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05867121 | Oct 2023 → Mar 2026 | gastric cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7496353 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867121 ↗ |
| Route | Intravenous | “RO7496353, and atezolizumab, given as an intravenous (IV) infusion” NCT05867121 ↗ |